Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its 20-valent pneumococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent infectious diseases caused by 20 different pneumococcal serotypes in infants and children aged between 2 months to 5 years.
Pfizer’s Prevnar-20, a similar product, has been approved for marketing in global markets, including Hong Kong, China, as of April 2023. Kangtai’s vaccine is classified under registration category 2.2, indicating it is an improved version of an existing vaccine that aims to enhance safety, efficacy, or quality, and demonstrates clear clinical advantages. It remains to be seen how Kangtai’s vaccine, which will be offered in a 0.5ml dose per person, will compete with Pfizer’s Prevnar-20, which has the same dosage. – Flcube.com
